Clinical Trial Update: ACE527 Safety and Immunogenicity Study [Phase 1]

View source ↗

Summary

Phase 1 safety and immunogenicity study of the ACE527 vaccine for Enterotoxigenic Escherichia coli infection has completed, reporting initial safety and immune …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Enterotoxigenic Escherichia Coli Infection

Drugs mentioned

• ACE527 (ACE527)

Snippet

Sponsor: TD Vaccines A/S | Conditions: Enterotoxigenic E. Coli (ETEC) Infection | Phase 1 | Status: COMPLETED